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Abstract 29 
Prostate cancer (PCa) is the most common malignancy affecting men in the western world. 30 
While radical prostatectomy and radiation therapy can successfully treat a majority of patients, 31 
up to ~30% will experience local recurrence or metastatic disease. Prostate carcinogenesis and 32 
progression is typically an androgen dependent process. For this reason, therapies for recurrent 33 
PCa target androgen biosynthesis and androgen receptor function. Whilst such androgen 34 
deprivation therapies (ADT) are effective initially, the duration of response is typically ≤24 35 
months. While ADT and taxane based chemotherapy have delivered survival benefits, 36 
metastatic prostate cancer remains incurable. Therefore it is essential to establish the cellular 37 
and molecular mechanisms which enable localized prostate cancers to invade and disseminate. 38 
It has long been accepted that metastases requires angiogenesis. In this review we will examine 39 
the essential role for angiogenesis in PCa metastases and in particular we will focus on current 40 
understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and 41 
metastatic PCa. We will highlight recent advances in understanding the role of VEGF in 42 
regulating interaction of cancer cells with tumor-associated immune cells during metastatic 43 
process of PCa.  We will summarize the established mechanisms of transcriptional and post-44 
transcriptional regulation of VEGF in prostate cancer cells and will outline the molecular insights 45 
obtained from pre-clinical animal models of prostate cancer. Finally we will summarize the 46 
current state of anti-angiogenesis therapies for PCa and how existing therapies impact on 47 
VEGF signalling.   48 
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Prostate cancer: molecular mechanisms of carcinogenesis and the role of androgens 49 
Prostate cancer (PCa) is the most common malignancy affecting western men (Ferlay, et al. 50 
2013; Siegel, et al. 2015) and is estimated to account for over 220,000 new cases and 27,000 51 
deaths in the United States in 2015. Advances in early diagnosis (Carter, et al. 2013; 52 
Heidenreich, et al. 2013), surgical, radio-, chemo- and immuno- therapies (reviewed in Lorente 53 
and De Bono 2014; Stewart and Boorjian 2014), are improving patient survival. However, the 54 
aging demographics of western countries suggest PCa will remain a leading cause of cancer 55 
related mortality in men. Although >90% of PCa are diagnosed as androgen responsive acinar 56 
adenocarcinoma (Humphrey 2012), the disease is clinically heterogeneous. Indeed it is 57 
currently not possible to accurately distinguish high risk prostate tumors, which require 58 
extensive therapeutic intervention, from patients with low risk indolent tumors, many of which 59 
would not require any therapy (Cuzick, et al. 2014; Draisma, et al. 2009; Tombal, et al. 2014; 60 
Weiner, et al. 2015). Therefore most men with clinically localized PCa undergo radical 61 
prostatectomy or radiotherapy with curative intent (Boorjian, et al. 2012; Heidenreich, et al. 62 
2014). Yet, it has been estimated that between 20-30% of cases will experience recurrence 63 
(Boorjian et al. 2012). Following local recurrence and metastasis, androgen deprivation therapy, 64 
achieved medically or through orchiectomy, is typically effective for <24 months by which time 65 
progression to the more detrimental form of castrate resistant PCa (CRPC) is common (Ahmed, 66 
et al. 2014). PCa becomes hormone refractory and cancer cells acquire the ability to invade and 67 
metastasize to lymph nodes and distant organs (Wegiel, et al. 2005).  68 
The importance of androgen signalling in prostate carcinogenesis has long been 69 
recognized (Huggins and Hodges 1941). In the intervening decades it became apparent that 70 
androgen signalling plays essential roles in localized and metastatic PCa (Wang, et al. 2009). 71 
The androgen receptor (AR) is a member of the ligand dependent transcription factor family of 72 
nuclear receptors which also includes the estrogen (ERα/ERβ) and progesterone (PR) 73 
receptors, lipophilic ligands (retinoids, vitamin D) and orphan receptors for which ligands have 74 
not been identified. In the presence of an agonist, nuclear receptors regulate gene expression 75 
by recruiting epigenetic coregulator proteins with histone lysine acetyltransferase (KAT), 76 
methyltransferase (KMT) and demethylase (KDM) activity. Consistent with the essential role 77 
played by androgens and the AR in hormone dependent (Yu, et al. 2010) and refractory PCa 78 
(Wang et al. 2009), nuclear receptor coregulators have also been implicated in prostate 79 
carcinogenesis and progression (Debes, et al. 2003; Heemers, et al. 2007; Rahman, et al. 80 
2003). KDMs are key coregulators of AR and ER transcriptional activation and repression 81 
(Cheng and Blumenthal 2010; Kooistra and Helin 2012). A subset of KDMs, including 82 
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KDM1A/LSD1, are over-expressed in PCa (Kahl, et al. 2006; Kashyap, et al. 2013; Metzger, et 83 
al. 2005). Although KDM1A acts predominantly as a transcriptional corepressor, KDM1A can act 84 
as a coactivator for AR (Metzger et al. 2005) and ERα (Perillo, et al. 2008) dependent upon 85 
promoter context (Cai, et al. 2011). Consistent with this there is evidence that KDM1A can 86 
contribute to hormone refractory PCa by sensitizing prostate cells to lower androgen levels (Cai 87 
et al. 2011; Cai, et al. 2014). Androgen and estrogen receptors are known to cooperate in gene 88 
regulation in PCa and can define transcriptional signatures associated with aggressive disease 89 
(Setlur, et al. 2008). As we will discuss in detail later, KDM1A appears to promote PCa 90 
recurrence in part by enhancing androgen-regulated VEGF expression (Kashyap et al. 2013). 91 
With a clear clinical need for new treatments, nuclear receptor epigenetic coregulators and 92 
related proteins are attractive therapeutic targets, due to their feasibility as ‘druggable’ targets 93 
(Asangani, et al. 2014; Dawson and Kouzarides 2012; Rotili, et al. 2014). For this reason 94 
recently identified coregulator components of the AR-signaling complex represent potential new 95 
targets to circumvent resistance to existing therapies.  96 
Androgen deprivation therapies (ADT) are the standard treatment for locally advanced 97 
and metastatic PCa. ADT targets androgen receptor (AR) signaling pathways which are central 98 
to gene expression programs driving prostate tumour growth and metastasis. AR signaling 99 
persists in hormone refractory PCas which are resistant to ADT (Wang et al. 2009). Although 100 
androgen deprivation therapies impede tumor progression, hormone refractory cancers bypass 101 
androgen dependency and remain incurable. Recently introduced CRPC therapies include 102 
abiraterone, an inhibitor of a key enzyme in androgen biosynthesis, and the potent AR 103 
antagonist, enzalutamide. While both abiraterone and enzalutamide have demonstrated survival 104 
benefits in the CRPC context, the duration of response to these agents remains disappointing 105 
(de Bono, et al. 2011; Scher, et al. 2012). Furthermore, one consequence of prolonged systemic 106 
androgen blockade is the increasing emergence of neuroendocrine PCa which is associated 107 
with aggressive disease and poor prognosis (Beltran, et al. 2011). Whilst we now have 108 
unparalleled insight into the genomic complexity of PCa (Baca, et al. 2013; Barbieri, et al. 2012; 109 
Barbieri, et al. 2013; Berger, et al. 2011), there is therefore an urgent need to exploit this 110 
knowledge with a view to identifying novel approaches to prevent or delay PCa metastases.  111 
 112 
Transcriptional regulation of pro-angiogenesis pathways in prostate cancer 113 
Pro-angiogenic pathways are essential mediators of tumor growth and metastasis, and as a 114 
consequence the potential for therapies targeting the tumor vasculature has long been 115 
recognized (Folkman 1971; Folkman, et al. 1971). Both normal and pathologic angiogenesis is 116 
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regulated predominantly by the vascular endothelial growth factors (VEGF-A, -B, -C and -D) and 117 
their cognate cell surface receptors (VEGFR1, VEGFR2, VEGFR3) which can also be activated 118 
by neuropilins (Roskoski 2007). VEGF isoforms exhibit distinct receptor affinities and activate 119 
the intra-cellular receptor tyrosine kinase signalling cascade. The VEGFs and their receptors 120 
also play a role in PCa lymphangiogenesis (Burton, et al. 2008; Wong, et al. 2005). In this 121 
review we will focus on the regulation and function of VEGFA (also referred to as simply VEGF) 122 
in angiogenesis. VEGF is over-expressed in a variety of haematological malignancies 123 
(Krejsgaard, et al. 2006) and the vast majority of solid tumors including PCa (Wegiel et al. 124 
2005)(Figure 1) where it is associated with poorer outcomes (Duque, et al. 1999; Green, et al. 125 
2007). In prostate, in addition to its expression in blood and lymphatic endothelial cells, VEGF is 126 
also expressed at low levels in prostatic glandular epithelial cells and in nonvascular cells such 127 
as macrophages, fibroblast and mast cells (Hrouda, et al. 2003). Chronic prostatic inflammation 128 
and the infiltration of macrophages and other immune cells that express high level of VEGF is 129 
believed to be an important event during the malignant transformation. The increased 130 
production of cytokines such as interleukin-6 is believed to induce VEGF expression in the 131 
infiltrating immune cells (Cohen, et al. 1996). It has been shown that bacterial 132 
lipopolysaccharide (LPS) induces the expression of Toll-like receptors (TLRs) in human prostate 133 
epithelial PC3 cells after exposure to bacterial infection. This increased expression of TLRs is 134 
able to induce VEGF expression which in turn triggers the proliferation and migratory ability of 135 
PCa cells (Pei, et al. 2008). 136 
The VEGF promoter is regulated by a multiple transcription factor complexes and the 137 
function of the hypoxia-inducible factors (HIFs) in the regulation of VEGF expression is well 138 
understood (Forsythe, et al. 1996; Gray, et al. 2005). However over the last decade it has 139 
become apparent that the VEGF promoter can be regulated by multiple members of the nuclear 140 
receptor family, including the AR (Eisermann, et al. 2013), estrogen (ERα/cMyc) (Buteau-141 
Lozano, et al. 2002; Dadiani, et al. 2009), progesterone (Wu, et al. 2004), vitamin D (Cardus, et 142 
al. 2009) and the liver-X receptors (LXR) (Walczak, et al. 2004). Consistent with this, animal 143 
studies have indicated a role for androgens and estrogen in prostate vascularization (Daehlin, et 144 
al. 1985). In this context it is interesting to note that nuclear receptor-coregulator complexes can 145 
regulate splicing events (Auboeuf, et al. 2004; Auboeuf, et al. 2002). Thus a role for aberrant 146 
recruitment of nuclear receptor-complexes to the VEGF promoter in the induction of pro-147 
angiogenic VEGF splicing during carcinogenesis cannot be excluded (Figure 2).  148 
Interestingly, pro- and anti-angiogenic VEGF splice forms have been identified (Bates et 149 
al 2002), which are differentially regulated in cancers, including in PCa (Mavrou, et al. 2014; 150 
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Woolard, et al. 2004) and which may be key to the development of future therapies targeting 151 
pro-angiogenic VEGF function (Harper and Bates 2008). In the terminal exon of the vegf gene 152 
(Exon 8) there are two potential splice sites. A proximal splice site (PSS) encodes 6 amino acids 153 
(CDKPRR) before a stop codon is reached, resulting in isoforms such as VEGF-A165a. The use 154 
of the PSS results in generation of angiogenic isoforms that increase vascular permeability, 155 
stimulate vessel growth and result in vasodilatation. Further into the terminal exon, a distal 156 
splice site (DSS), 66 bases downstream of the PSS, results in an alternative open reading 157 
frame of the same size (6 amino acids, SLRTKD), resulting in a different C-terminus to the 158 
protein. And VEGF-A165b This switches the protein to an anti-angiogenic one that can inhibit 159 
vasodilatation (Woolard et al. 2004), and reduce permeability (Oltean, et al. 2012). The splice 160 
variants are differentially regulated (e.g. SRPK1 stimulates splicing to VEGF-A165a, and Clk1/4 161 
to VEGF-A165b) (Nowak, et al. 2010; Nowak, et al. 2008) and are differentially reguated post-162 
transcriptionally – e.g. by T-cell intracellular Antigen 1, an RNA binding protein that differentially 163 
regulates translation and splicing of VEGF through activation by ras (Hamdollah Zadeh, et al. 164 
2015).  165 
 166 
Post-transcriptional Regulation of VEGF in Prostate Cancer 167 
Regulation of VEGF expression can occur at multiple points between transcription and 168 
translation, these regulatory effects broadly fall into three different areas; pre-mRNA processing 169 
(alternative splicing as discussed above), mRNA transcript stability and control of translation. 170 
The latter two categories will be discussed in this section, with a focus on the mechanisms of 171 
VEGF post-transcriptional regulation in PCa.  172 
Variations in mRNA transcript stability are commonly seen as a cellular-response to 173 
environmental changes such as stress and nutrient availability, acting as a rapid response to 174 
maintain protein homeostasis. VEGF is tightly regulated at the transcript level and whilst the 175 
reported half-life is short, 15-40 minutes in vitro, this can be substantially extended during 176 
periods of hypoxia and nutrient withdrawal (Dibbens, et al. 1999; Ikeda, et al. 1995; Levy, et al. 177 
1996; Shima, et al. 1995). AU-rich elements (ARE) within the 3’UTR of the VEGF transcript 178 
along with other elements within the coding and untranslated regions are potential targets for a 179 
range of RNA binding proteins, resulting in both positive and negative effects on transcript 180 
stability (Chang, et al. 2013; Claffey, et al. 1998; Coles, et al. 2004; Fellows, et al. 2012; 181 
Goldberg-Cohen, et al. 2002; King 2000; Onesto, et al. 2004; Shih and Claffey 1999). Hypoxia-182 
dependent regulation of transcript stability has been well characterised in a number of cancer 183 
types and recently reviewed in (Arcondeguy, et al. 2013). 184 
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Interestingly, two less well characterised methods of hypoxia-independent regulation of 185 
VEGF transcript stability have been observed in studies of PCa. The first occurring when DU145 186 
PCa cells were subjected to glucose deprivation. Under these conditions, VEGF transcript 187 
stability was increased as a result of the stimulation of AMP-activated Protein Kinase (AMPK), 188 
through an as yet unknown mechanism (Yun, et al. 2005). Further to this, an isoform of the 189 
Wilm’s Tumour Suppressor Gene (WT1-A) was found to modestly increase VEGF transcript 190 
stability in a hormone enhanced mechanism, when WT1 was stably over-expressed in LNCaP 191 
PCa cells. Over-expression of other WT1 isoforms lacking the third of four zinc finger domains 192 
were unable to mediate VEGF stability, indicating the potential importance of zinc finger 193 
domains in this regulatory mechanism (Cash, et al. 2007). 194 
Eukaryotic protein translation predominantly depends on the m7G cap structure of the 195 
mRNA and assembly of the translation initiation complex (cap-dependent translation). However, 196 
alternative mechanisms of cap-independent translation have evolved, in order to maintain or 197 
activate the translation of essential proteins during periods of cellular-stress when cap-198 
dependent translation is impaired (reviewed (Van Der Kelen, et al. 2009)). Cap-independent 199 
mechanisms depend upon the presence of Internal Ribosome Entry Sites (IRES) to enable 200 
initiation of translation, whilst originally identified in viruses, multiple eukaryotic mRNAs including 201 
VEGF are reported to contain IRES sequences (Jang, et al. 1988; Pelletier and Sonenberg 202 
1988). The VEGF mRNA 5’UTR features two IRESs; IRES-A and IRES-B 293 and 947 203 
nucleotides upstream of the canonical AUG start site respectively, the position of IRES-B is also 204 
just over 40 nucleotides upstream of an alternative CUG start codon (Akiri, et al. 1998; Huez, et 205 
al. 1998; Miller, et al. 1998). A single-nucleotide polymorphism (SNP) of the VEGF gene (-634 206 
C>G substitution) has been linked with increased risk of PCa (Sfar, et al. 2006). This SNP was 207 
found to impair IRES-B function, reducing translation initiated from the alternative CUG start 208 
codon (Lambrechts, et al. 2003). Furthermore, a 17 nucleotide sequence within VEGF IRES-A 209 
has been shown to promote the formation of an intramolecular G-quadruplex structure (Morris, 210 
et al. 2010). G-quadruplex formation potentially regulates multiple aspects of RNA regulation, in 211 
the case of VEGF, mutations of this 17 nucleotide sequence prevents G-quadruplex formation 212 
and results in inhibition of IRES-A function (Morris et al. 2010). The contribution of G-quadruplex 213 
regulation to VEGF expression in PCa remains to be determined, but given the role of IRESs in 214 
mediating VEGF translation under stress conditions these intramolecular structures warrant 215 
further investigation.  216 
Translation efficiency of VEGF can be further modified by microRNAs (miRNAs), a class 217 
of small non-coding RNA. MicroRNAs regulate translation by binding to specific sequences 218 
Page 7 of 33
within the target mRNA, usually these binding sites reside within the 3’UTR but can also occur 219 
in the 5’UTR and coding regions (Tay, et al. 2008). Target binding is mediated by the miRNA-220 
associate RNA Induced Silencing Complex (mi-RISC) and results in either the repression of 221 
translation or mRNA degradation, with the net result of both processes being reduced protein 222 
expression (reviewed in (Huntzinger and Izaurralde 2011)). Analysis of prostate tissue and cell 223 
lines have identified multiple miRNAs, the expression of which are consistently altered in 224 
prostate tumors, leading to further analysis of downstream gene targets and their potential 225 
contribution to carcinogenesis. Szczyrba et al. reported a significant reduction of miR-29b 226 
expression in PCa and subsequently demonstrated miR-29b as a direct regulator of VEGF in 227 
PCa cell lines LNCaP and DU145 (Szczyrba, et al. 2010; Szczyrba, et al. 2013).   228 
In addition to miR-29b, the VEGF transcript is predicted to contain binding sites for 229 
multiple miRNA types (as highlighted in Figure 2C), such as miR-145 and miR-205, the 230 
expression of which are reduced in PCa and have been shown to regulate VEGF in other 231 
cancer types (Boll, et al. 2013; Fan, et al. 2012; Szczyrba et al. 2010; Yue, et al. 2012). 232 
However, it remains to be determined how effectively these miRNAs repress VEGF translation 233 
in PCa. Indeed it is also possible that such repression may only occur in specific cellular 234 
contexts. In relation to this latter point, an investigation of the anti-angiogenic effects of 235 
melatonin on hypoxic PCa PC3 cells, determined a melatonin-dependent increase in the 236 
expression of miR-374b. Subsequent studies confirmed miR-374b mediated the anti-angiogenic 237 
effects of melatonin by inhibiting VEGF expression (Sohn, et al. 2015).  238 
  239 
VEGF, bone metastasis and niches 240 
The dissemination of cancer cells from the primary tumor site to distant organs is a key step 241 
during cancer progression. Once cancer cells invade into the bone, liver and lung, no curable 242 
treatment exists. PCa cells preferentially invade into the bone. It is estimated that 70% of 243 
patients with metastatic PCa develop bone metastasis (Semenas, et al. 2012; Shah, et al. 244 
2004). These studies suggest that altered VEGF expression in endothelial cells leads to 245 
impaired blood vessel invasion. As blood vessels serve as a way of transporting circulating 246 
cancer cells, the increased blood vessels beds will increase the transporting of cancer cells into 247 
the blood-vessels enriched organs including liver and lung.   248 
The spread of PCa cells metastasis to bone is a complex process involving local 249 
infiltration of tumour cells into adjacent tissue, migration from the primary tumour site into 250 
vessels (intravasation), survival and dissemination through the vascular system, extravasation, 251 
and finally invasion and subsequent proliferation in bone. There is increasing evidence showing 252 
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that VEGF signaling plays an important role in promoting bone metastasis of PCa. It has been 253 
shown that VEGF signalling initiate metastatic niches to allow cancer cells to home to the bone 254 
marrow during bone metastasis (Kaplan, et al. 2005). VEGF may stimulate the proliferation and 255 
migration of the infiltrated immune cells that secondarily infiltrate tumor tissue to promote PCa 256 
cells to enter into the blood vessels and to disseminate into the distant organs. The expression 257 
of VEGF is also detected in osteoblasts (Maes, et al. 2010).   258 
Previous reported studies have shown that VEGF has autocrine and paracrine effects on 259 
the growth and survival activity of osteoblasts (Dai, et al. 2004; Midy and Plouet 1994; Street, et 260 
al. 2002). Further, bone morphogenesis proteins (BMPs) contribute to PCa–mediated 261 
osteoblastic activity in vitro partly through VEGF (Dai et al. 2004). It has also been shown that 262 
VEGF contributes to PCa induced bone remodelling at bone metastatic sites in mouse models 263 
(Kitagawa, et al. 2005). These studies suggest that altered expression of VEGF in both PCa 264 
cells and cells of invaded bone tissue may result in increased activity of bone cells, leading to 265 
an imbalance of bone formation and resorption. VEGF is also functionally linked to adhesion 266 
molecules such as fibronectin and extracellular matrix. These proteins may assist tumour cells 267 
to attract and adhere to the bone microenvironment through VEGF receptors VEGFR1 and 268 
VEGFR2 (Chen, et al. 2004; Sterling, et al. 2011). 269 
VEGF, in addition to its angiogenic role, suppresses the immune system (Figure 3). It 270 
has been shown that VEGF directly or indirectly exerts multiple immunosuppressive activities. It 271 
has been reported that VEGF secreted by mouse tumor cells prevented dendritic cells from 272 
maturing, thus hampering tumor antigen presentation (Gabrilovich, et al. 1996). VEGF 273 
expression is present in cytotoxic T cells and it has been shown that increased expression of 274 
VEGF and VEGFR2 suppressed the activity of T cell receptor CD47 and cytotoxic T cell function 275 
(Kaur, et al. 2014). Altered VEGF signaling may also suppress the function of dendritic cells and 276 
indirectly inhibit T-cell infiltration of tumor tissue. Consistent with this, VEGF blockade has 277 
resulted in increased T-cell homing to tumors and has enhanced the efficacy of immunotherapy 278 
in mouse models (Mellman, et al. 2011).  279 
 280 
Mouse models of PCa and relevant aspects of angiogenesis/VEGF signalling  281 
The need for a better understanding of the molecular and pathological events involved in PCa 282 
progression has driven the development of animal models. Animal models of PCa can be 283 
distinguished into two broad groups, the first being xenograft of human PCa into immune-284 
compromised mice and the second genetically modified mice (GEM) that will develop prostatic 285 
cancer during their lifetime (Gingrich, et al. 1999; Gray, et al. 2004). Although informative, 286 
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mouse models have several limitations. These include the inability to encompass the full 287 
complexity of the human disease and the inherent resistance to the development of invasive 288 
PCa. Nevertheless, several mouse models have been developed for the study of PCa and these 289 
have been comprehensively reviewed elsewhere (Berman-Booty and Knudsen 2015; 290 
Grabowska, et al. 2014; Wu, et al. 2013). Here we will focus on those that more closely 291 
recapitulate the progression of the human disease (Table 1).  292 
 Several xenograft animal models have been developed to recapitulate progression of 293 
human PCa. The PC3 and LNCaP, derived from an osteolytic and a lymph node metastasis 294 
respectively, are two of the most frequently used cell lines used to study PCa (Kaighn et al., 295 
1979, Horoszewicz, 1980). Several sublines were derived from these original cell lines with 296 
enhanced tumorigenicity in vivo, including LNCaP-Pro3-5, LNCaP-LN3-4, PC3M, PC-3M-LN4 297 
(Wu et al. 2013). LNCaP-LN3 and LNCaP-Pro5 xenografts are thought to resemble prostatic 298 
adenocarcinomas as xenografts express AR and PSA and are shown to be androgen sensitive 299 
(Pettaway et al., 1996, Yonou et al., 2001). Intravenous or orthotopic injections of LNCaP in 300 
mice are able to metastasize to subcutaneously implanted human adult bone but not murine 301 
bone (Yonou, et al. 2001). Interestingly, one androgen independent subline, LNCaP C4-2, is 302 
able to metastasize to the bone and cause osteoblastic lesions (Thalmann, et al. 1994). PC3M 303 
xenografts are androgen-insensitive and stain negative for PSA and AR, with the subline PC-304 
3M-LN4 forming bone, lymphatic and lung metastases after orthotopic or intravenous injection 305 
into mice (Pettaway et al., 1996, Yonou et al., 2001). Overall, this data suggests LNCaP 306 
xenografts may model an earlier stage PCa progression than PC3.  307 
The WISH-PC2 xenograft model was derived from a poorly differentiated 308 
adenocarcinoma that was treated with androgen deprivation and histologically consistent with a 309 
neuroendocrine (NE) PCa upon implantation (Pinthus et al., 2000). WISH-PC2 orthotopic 310 
xenografts are able to metastasize to the lymph nodes, lung and liver, and when injected locally 311 
can form tumors within bone and liver tissues (Pinthus et al., 2000). Other NE PCa relevant 312 
models include the LTL352 and LTL370 derived from metastatic NE PCa resected from urethral 313 
and penile areas, respectively. Like WISH-PC2, these xenografts stain negative for PSA and 314 
AR, and can grow in androgen deprived mice with rapid doubling time. A major limitation of 315 
xenograft models is that most tissues are obtained from advanced and aggressive PCas and 316 
therefore tend to model later stages of the disease. Furthermore, one intrinsic limitation of 317 
xenografts is that these systems depend upon effective murine vascularization of human cancer 318 
cell masses and may therefore not fully recapitulate all aspects of tumors in patients. 319 
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Nevertheless, the xenograft models, especially LNCaP xenografts, have been instrumental for 320 
understanding PCa and for many preclinical studies.  321 
 Transgenic mouse models can approximate the different stages of PCa progression, 322 
from low grade to high grade prostate intraepithelial neoplasia (PIN), adenocarcionoma and 323 
metastatic cancer. Early models utilised expression of viral oncogenes (such as small and large 324 
SV40 tumour antigens under the control of the prostate-specific probasin (PB) promoter) in the 325 
prostate epithelium. The viral oncogene models differ from human PCa as they present a rapid 326 
progression of the disease and predominant NE differentiation. However, they have been 327 
recognised as relevant models for PCa, and very useful for the investigation of CRPC that 328 
progresses to NE carcinoma (Berman-Booty and Knudsen 2015). In the TRAMP (transgenic 329 
adenocarcinoma mouse prostate) model a rapid progression of PCa with lymph node and lung 330 
metastasis was observed, with bone metastasis only reported for the FVB mouse background 331 
(Gingrich, et al. 1996). The TRAMP mice also respond to castration and can progress to 332 
hormone refractory disease associated with NE differentiation and increased metastasis rate 333 
(Gingrich, et al. 1997; Kaplan-Lefko, et al. 2003). Similarly some of LADY mouse model lines 334 
(e.g 12T-7s-f/PB-hepsin, and 12T10), drive invasive carcinoma and NE carcinoma with 335 
metastasis to the liver, lung and bone (Klezovitch, et al. 2004; Masumori, et al. 2001). The 336 
second generation mouse models were based on human PCa genetic alterations, including loss 337 
of the tumour suppressor genes PTEN, NKX3.1, p53, Rb and amplification of the MYC 338 
oncogene. Interestingly, none of the single gene deletion models shows a significant PCa 339 
phenotype but their synergistic inactivation results in the cancer onset. For instance, 340 
simultaneous inactivation of p53 and Rb results in the formation of highly metastatic tumors that 341 
are resistant to castration and showing NE differentiation (Zhou, et al. 2006). The best of these 342 
new models incorporate multiple genetic lesions with Cre-gene targeting. The most utilised 343 
models are based on the conditional targeted deletion of PTEN and they seem to recapitulate 344 
the disease progression seen in humans, including the development of CRPC with activation of 345 
PI3K/Akt signalling (Grabowska et al. 2014; Wang, et al. 2003). 346 
 Despite being the main angiogenic factor involved in PCa progression and metastasis, 347 
few studies have examined the role of VEGF in PCa animal models. Xenografts of PCa and 348 
benign prostate primary tissue exhibit maturation of vascularisation at 30 days with the 349 
presence of small vessel of human origin containing red blood cells within (Gray et al. 2004; 350 
Montecinos, et al. 2012; Presnell, et al. 2001). These xenograft tumors exhibit a surge of 351 
angiogenesis at day 6 post-implantation into mice, preceded by an up-regulation of VEGF in the 352 
stromal counterpart of the tumour at day 2 (Montecinos et al. 2012). A further increase in VEGF 353 
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protein is also shown to modulated through the addition of human testosterone pellets implanted 354 
into castrated mice when compared to the controls (Montecinos et al. 2012). This data suggests 355 
a role for VEGF in angiogenesis establishment and PCa progression through androgen 356 
regulation. During androgen deprivation (AD), a marked reduction in microvascular density 357 
(MVD) is seen after 2 days followed by vascular reestablishment from days 7 and 14 (Godoy, et 358 
al. 2011). The expression of VEGF and VEGFR2 increased in epithelial cells 2 days post AD 359 
suggesting a compensatory role for these molecules in survival of PCa and progression (Godoy 360 
et al. 2011). This data suggests androgen-dependent and independent mechanisms for VEGF 361 
induction. As described above, most xenograft models use primary PCa tissue, however PCa 362 
cell lines have been exploited in a subset of studies. For example, PC3 has been used to 363 
investigate the use of drugs to inhibit VEGF signalling (Anai, et al. 2011; Pang, et al. 2011a; 364 
Pang, et al. 2011b). Similarly, the LNCaP-LN3 orthotopic xenograft has been used to evaluate 365 
the response of bone metastasis to the anti-VEGF receptor antibody DC101 (Sweeney, et al. 366 
2002).  367 
The TRAMP model has been used to study angiogenic responses. Pathologically, the 368 
TRAMP mice of the FVB genetic background show highly vascularised tumors with early onset 369 
of angiogenic switch, together with loss of E-cadherin expression indicative of epithelia-to-370 
mesenchymal transition (EMT) (Chiaverotti, et al. 2008; Gingrich et al. 1999; Kaplan-Lefko et al. 371 
2003). Based on histological and immunohistochemical analysis, TRAMP mice tumors also 372 
show high VEGF and FGF-2 expression, with increased microvessel density. Importantly, these 373 
mice recapitulate the stimulation of angiogenesis observed in the aged mouse prostate, which is 374 
sensitive to treatment with antiangiogenic drugs (TNP-470 alone or in combination with 375 
SU5416) and finasteride (Montico, et al. 2014). The role of VEGF in advanced PCa has also 376 
been studied in Pten conditional knockout mice. PCa cells in these mice express the VEGF 377 
receptor NRP2 and activate signalling leading to expression of the Polycomb transcriptional 378 
repressor Bmi-1, which is implicated in the onset of PCa induced by Pten deletion (Goel, et al. 379 
2012). This highlights an important role of VEGF/NRP2 signalling in PCa and the need to 380 
develop new therapies specifically targeting of this pathway (Geretti, et al. 2010).  381 
 382 
Anti-VEGF therapies in clinical management of prostate cancer  383 
High tumor VEGF levels have been associated with poor treatment outcome in PCa and 384 
higher VEGF serum levels has been described in patients with metastatic disease than in those 385 
with localized disease (Duque et al. 1999; Green et al. 2007). The use of anti-VEGF therapies in 386 
preclinical and clinical studies has been associated with increased side effects including 387 
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hypertension, gastrointestinal bleeding, intestinal perforation and pulmonary embolism 388 
(Mangoni, et al. 2012; Ogita, et al. 2012). Although bevacizumab has shown some promise with 389 
improved progression free survival, no significant improvement in overall survival has been 390 
achieved even in combination therapies (reviewed in Armstrong, et al. 2013; Small and Oh 391 
2012). A newer anti-angiogenesis agent derived from the extra-cellular domains of the VEGFR 392 
(aflibercept) in combination with docetaxel and prednisone also offered no improvement in 393 
overall survival (Tannock, et al. 2013). Yet given the comparative success of trials of newer 394 
agents targeting VEGF signalling in other cancer types (Grothey, et al. 2013; Qi, et al. 2011), 395 
further studies are required of these agents in the PCa setting. Indeed Cediranib, a VEGFR 396 
receptor tyrosine kinase inhibitor was tested in a phase II trial on docetaxel pre-treated CRPC 397 
patients as monotherapy and was found to be well tolerated with some anti-tumour activity 398 
(Dahut, et al. 2013). There are ongoing phase II trial using Cediranib in combination with 399 
docetaxel plus prednisone or with abiraterone (ClinicalTrials.gov identifier NCT00527124 and 400 
NCT01574937 respectively) in hormone refractory PCa. A phase I trial combining abiraterone 401 
with cabozantinib is also ongoing (NCT01574937) likewise a phase II trial combining 402 
bevacizumab, lenalidomide, docetaxel, and prednisone (ART-P) for treatment of metastatic 403 
castrate-resistant PCa (NCT00942578). Given the immuno-suppressive and pro-angiogenic 404 
actions of VEGF new combinations therapies targeting VEGF signalling and promoting immune 405 
function are likely to emerge (reviewed in Cheng and Fong 2014). However further studies are 406 
required to not only identify the optimal therapeutic combinations, but also the sequencing of 407 
therapies with respect to cytotoxic chemotherapy use. This is of particular significance given 408 
that reduced tumor angiogenesis achieved by anti-VEGF therapies may impair optimal delivery 409 
of chemotherapeutics within tumor masses (Carmeliet and Jain 2011).  410 
 411 
Effect of radiation therapy on angiogenesis 412 
Radiation therapy is an important treatment modality for the management of 413 
malignancies. Preclinical studies have demonstrated that in addition to inducing cell death, 414 
radiation also damages tumor vasculature and prevents tumor angiogenesis (El Kaffas, et al. 415 
2013). However local treatment failures occur in many patients after initial response to radiation 416 
therapy. Such recurrent diseases are noted to be more aggressive, resistant to therapy and 417 
have poor prognosis (Punnen, et al. 2013). Recurrence has been partly attributed to subsequent 418 
improvements in the tumour vasculature induced by radiation treatment. It has been reported 419 
that following radiation therapy, pro-angiogenic factors including VEGF are induced in remaining 420 
malignant and stromal cells in the tumour. Mobilization of pro-angiogenic CD11b positive 421 
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myelomonocytic cells from the bone marrow to the tumour stroma has also been noted to 422 
improve the revascularization of the tumor bed (Martin 2013 and references therein). Thus anti-423 
VEGFs such as bevacizumab may both sensitize the tumor to radiotherapy and block post-424 
therapy re-vascularization (Zhuang, et al. 2014). However the combination of radiation therapy 425 
with anti VEGF therapies in PCa has not been extensively studied clinically. A phase II study 426 
reported by Vuky and colleagues (2012) examined long-term androgen suppression with 427 
bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk PCa with acute and 428 
late toxicity as end points. It was reported that the addition of bevacizumab did not appear to 429 
worsen the effect of radiotherapy in PCa. A phase I trial which has recently completed 430 
recruitment is also studying the toxicity associated with the combination of sunitinib with 431 
hormone ablation and radiotherapy in patients with PCa (ClinicalTrials.gov. identifier 432 
NCT00631529). More trials with overall survival as endpoint are needed to assess the effect of 433 
combining anti VEGFs with radiation therapy in prostate CRPC. 434 
 435 
Conclusion 436 
Tumors must exploit pro-angiogenesis pathways to metastasize. For this reason targeting 437 
VEGF signalling remains an attractive approach to prevent, delay or reverse tumor metastasis. 438 
The clinical utility of anti-angiogenesis therapy for metastatic PCa has been disappointing to 439 
date. Such therapies have almost exclusively targeted circulating VEGF or the tyrosine kinase 440 
activity of VEGF receptors. However recent advances in understanding of the regulation of 441 
VEGF in prostate cells (Kashyap et al. 2013) raises the potential to pharmacologically target 442 
epigenetic complexes involved in the hormonal regulation of VEGF expression. Indeed with the 443 
approval of the HDAC inhibitors, vorinostat(SAHA) and romidepsin, for the treatment of 444 
cutaneous T-cell lymphoma and with trials of epigenetic targeted therapies for PCa ongoing 445 
(Campbell and Tummino 2014), the simultaneous targeting of pro-androgenic, pro-estrogenic 446 
and pro-angiogenic pathways with small molecular inhibitors of nuclear receptor coregulators is 447 
an increasingly attractive approach.    448 
 449 
Acknowledgements: The authors acknowledge the financial support of the University of 450 
Nottingham, BBSRC, Cancer Research UK and the Swedish Foundation for International 451 
Cooperation in Research and Higher Education.  452 
  453 
Page 14 of 33
  454 
Page 15 of 33
References 455 
Ahmed A, Ali S & Sarkar FH 2014 Advances in androgen receptor targeted therapy for prostate 456 
cancer. J Cell Physiol 229 271-276. 457 
Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O & Levi BZ 1998 Regulation of vascular 458 
endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and 459 
alternative initiation of transcription. Oncogene 17 227-236. 460 
Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S & 461 
Rosser CJ 2011 Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for 462 
prostate cancer. In Urologic Oncology: Seminars and Original Investigations, pp 421-429: 463 
Elsevier. 464 
Arcondeguy T, Lacazette E, Millevoi S, Prats H & Touriol C 2013 VEGF-A mRNA processing, 465 
stability and translation: a paradigm for intricate regulation of gene expression at the post-466 
transcriptional level. Nucleic Acids Res 41 7997-8010. 467 
Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis V, Polikoff J, Damber JE, Belkoff 468 
L, Nordle O, Forsberg G, et al. 2013 Long-term survival and biomarker correlates of 469 
tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic 470 
metastatic castration-resistant prostate cancer. Clin Cancer Res 19 6891-6901. 471 
Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-472 
Romans K, Dhanireddy S, Engelke C, et al. 2014 Therapeutic targeting of BET bromodomain 473 
proteins in castration-resistant prostate cancer. Nature. 474 
Auboeuf D, Dowhan DH, Kang YK, Larkin K, Lee JW, Berget SM & O'Malley BW 2004 475 
Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice 476 
site choice in target genes. Proc Natl Acad Sci U S A 101 2270-2274. 477 
Auboeuf D, Honig A, Berget SM & O'Malley BW 2002 Coordinate regulation of transcription and 478 
splicing by steroid receptor coregulators. Science 298 416-419. 479 
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, 480 
MacDonald TY, Ghandi M, et al. 2013 Punctuated evolution of prostate cancer genomes. Cell 481 
153 666-677. 482 
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, 483 
Stojanov P, Van Allen E, Stransky N, et al. 2012 Exome sequencing identifies recurrent SPOP, 484 
FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44 685-689. 485 
Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Gronberg H, Luo J, Visakorpi T & Rubin 486 
MA 2013 The mutational landscape of prostate cancer. Eur Urol 64 567-576. 487 
Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry 488 
S, Tagawa ST, et al. 2011 Molecular characterization of neuroendocrine prostate cancer and 489 
identification of new drug targets. Cancer Discov 1 487-495. 490 
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, 491 
Esgueva R, Pflueger D, Sougnez C, et al. 2011 The genomic complexity of primary human 492 
prostate cancer. Nature 470 214-220. 493 
Berman-Booty LD & Knudsen KE 2015 Models of neuroendocrine prostate cancer. Endocr 494 
Relat Cancer 22 R33-R49. 495 
Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von 496 
Bergen M, Horn F, et al. 2013 MiR-130a, miR-203 and miR-205 jointly repress key oncogenic 497 
pathways and are downregulated in prostate carcinoma. Oncogene 32 277-285. 498 
Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief 499 
C & Zorn KC 2012 A critical analysis of the long-term impact of radical prostatectomy on cancer 500 
control and function outcomes. Eur Urol 61 664-675. 501 
Burton JB, Priceman SJ, Sung JL, Brakenhielm E, An DS, Pytowski B, Alitalo K & Wu L 2008 502 
Suppression of prostate cancer nodal and systemic metastasis by blockade of the 503 
lymphangiogenic axis. Cancer Res 68 7828-7837. 504 
Page 16 of 33
Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J & Perrot-Applanat M 2002 Transcriptional 505 
regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer 506 
cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62 4977-507 
4984. 508 
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Nelson PS, Liu XS, Brown M & Balk SP 509 
2011 Androgen receptor gene expression in prostate cancer is directly suppressed by the 510 
androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20 457-511 
471. 512 
Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen MW, Zhang J, Ahmed M, Wang Y, et al. 513 
2014 Lysine-specific demethylase 1 has dual functions as a major regulator of androgen 514 
receptor transcriptional activity. Cell Rep 9 1618-1627. 515 
Campbell RM & Tummino PJ 2014 Cancer epigenetics drug discovery and development: the 516 
challenge of hitting the mark. J Clin Invest 124 64-69. 517 
Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, Fernandez E & Valdivielso JM 518 
2009 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response 519 
element in the VEGF promoter. Atherosclerosis 204 85-89. 520 
Carmeliet P & Jain RK 2011 Molecular mechanisms and clinical applications of angiogenesis. 521 
Nature 473 298-307. 522 
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff 523 
P, Konety BR, Murad MH, et al. 2013 Early detection of prostate cancer: AUA Guideline. J Urol 524 
190 419-426. 525 
Cash J, Korchnak A, Gorman J, Tandon Y & Fraizer G 2007 VEGF transcription and mRNA 526 
stability are altered by WT1 not DDS(R384W) expression in LNCaP cells. Oncol Rep 17 1413-527 
1419. 528 
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, 529 
Park K, Kossai M, et al. 2014 The oestrogen receptor alpha-regulated lncRNA NEAT1 is a 530 
critical modulator of prostate cancer. Nat Commun 5 5383. 531 
Chang SH, Lu YC, Li X, Hsieh WY, Xiong Y, Ghosh M, Evans T, Elemento O & Hla T 2013 532 
Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional 533 
regulation of vascular endothelial growth factor-A expression and angiogenesis. J Biol Chem 534 
288 4908-4921. 535 
Chen J, De S, Brainard J & Byzova TV 2004 Metastatic properties of prostate cancer cells are 536 
controlled by VEGF. Cell Commun Adhes 11 1-11. 537 
Cheng ML & Fong L 2014 Beyond sipuleucel-T: immune approaches to treating prostate 538 
cancer. Curr Treat Options Oncol 15 115-126. 539 
Cheng X & Blumenthal RM 2010 Coordinated chromatin control: structural and functional 540 
linkage of DNA and histone methylation. Biochemistry 49 2999-3008. 541 
Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR & Balmain A 542 
2008 Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic 543 
adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 172 236-246. 544 
Claffey KP, Shih SC, Mullen A, Dziennis S, Cusick JL, Abrams KR, Lee SW & Detmar M 1998 545 
Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA 546 
stability. Mol Biol Cell 9 469-481. 547 
Cohen T, Nahari D, Cerem LW, Neufeld G & Levi BZ 1996 Interleukin 6 induces the expression 548 
of vascular endothelial growth factor. J Biol Chem 271 736-741. 549 
Coles LS, Bartley MA, Bert A, Hunter J, Polyak S, Diamond P, Vadas MA & Goodall GJ 2004 A 550 
multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding 551 
proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA 552 
stabilization. Eur J Biochem 271 648-660. 553 
Page 17 of 33
Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy 554 
FC, Holmberg L, et al. 2014 Prevention and early detection of prostate cancer. Lancet Oncol 15 555 
e484-492. 556 
Dadiani M, Seger D, Kreizman T, Badikhi D, Margalit R, Eilam R & Degani H 2009 Estrogen 557 
regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of 558 
estrogen receptor alpha and c-Myc. Endocr Relat Cancer 16 819-834. 559 
Daehlin L, Damber JE, Selstam G & Bergman B 1985 Testosterone-induced decrement of 560 
prostatic vascular resistance in rats is reversed by estrogens. Prostate 6 351-359. 561 
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer 562 
SD, Mulquin M, Wright J, et al. 2013 Phase II clinical trial of cediranib in patients with metastatic 563 
castration-resistant prostate cancer. BJU Int 111 1269-1280. 564 
Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS & 565 
Keller ET 2004 Vascular endothelial growth factor contributes to the prostate cancer-induced 566 
osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64 994-999. 567 
Dawson MA & Kouzarides T 2012 Cancer epigenetics: from mechanism to therapy. Cell 150 12-568 
27. 569 
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman 570 
OB, Jr., Saad F, et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. N 571 
Engl J Med 364 1995-2005. 572 
Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA & Tindall DJ 2003 p300 in prostate 573 
cancer proliferation and progression. Cancer Res 63 7638-7640. 574 
Dibbens JA, Miller DL, Damert A, Risau W, Vadas MA & Goodall GJ 1999 Hypoxic regulation of 575 
vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA 576 
elements. Mol Biol Cell 10 907-919. 577 
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E & de Koning H 2009 578 
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and 579 
context. J Natl Cancer Inst 101 374-383. 580 
Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D & Freeman MR 1999 Plasma 581 
levels of vascular endothelial growth factor are increased in patients with metastatic prostate 582 
cancer. Urology 54 523-527. 583 
Eisermann K, Broderick CJ, Bazarov A, Moazam MM & Fraizer GC 2013 Androgen up-584 
regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 585 
binding site. Mol Cancer 12 7. 586 
El Kaffas A, Giles A & Czarnota GJ 2013 Dose-dependent response of tumor vasculature to 587 
radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency 588 
power Doppler ultrasound. Angiogenesis 16 443-454. 589 
Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, Affolter T, Christensen J & 590 
Li G 2014 Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of 591 
castration resistant prostate cancer. BMC Cancer 14 742. 592 
Fan L, Wu Q, Xing X, Wei Y & Shao Z 2012 MicroRNA-145 targets vascular endothelial growth 593 
factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin 594 
(Shanghai) 44 407-414. 595 
Fellows A, Griffin ME, Petrella BL, Zhong L, Parvin-Nejad FP, Fava R, Morganelli P, Robey RB 596 
& Nichols RC 2012 AUF1/hnRNP D represses expression of VEGF in macrophages. Mol Biol 597 
Cell 23 1414-1422. 598 
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D 599 
& Bray F 2013 Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 600 
2012. Eur J Cancer 49 1374-1403. 601 
Folkman J 1971 Tumor angiogenesis: therapeutic implications. N Engl J Med 285 1182-1186. 602 
Folkman J, Merler E, Abernathy C & Williams G 1971 Isolation of a tumor factor responsible for 603 
angiogenesis. J Exp Med 133 275-288. 604 
Page 18 of 33
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD & Semenza GL 1996 Activation 605 
of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell 606 
Biol 16 4604-4613. 607 
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D & 608 
Carbone DP 1996 Production of vascular endothelial growth factor by human tumors inhibits the 609 
functional maturation of dendritic cells. Nat Med 2 1096-1103. 610 
Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L & Klagsbrun M 2010 A 611 
mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor 612 
bioactivity and inhibits tumor progression. Mol Cancer Res 8 1063-1073. 613 
Gingrich JR, Barrios RJ, Foster BA & Greenberg NM 1999 Pathologic progression of 614 
autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2 70-75. 615 
Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ & Greenberg NM 1997 Androgen-616 
independent prostate cancer progression in the TRAMP model. Cancer Res 57 4687-4691. 617 
Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, 618 
Rosen JM & Greenberg NM 1996 Metastatic prostate cancer in a transgenic mouse. Cancer 619 
Res 56 4096-4102. 620 
Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, 621 
Mohler JL & Smith GJ 2011 Androgen deprivation induces rapid involution and recovery of 622 
human prostate vasculature. American Journal of Physiology-Endocrinology and Metabolism 623 
300 E263-E275. 624 
Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh CC, Adisetiyo H, Roy-Burman P, 625 
Coleman IM, et al. 2012 VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of 626 
IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov 2 906-921. 627 
Goldberg-Cohen I, Furneauxb H & Levy AP 2002 A 40-bp RNA element that mediates 628 
stabilization of vascular endothelial growth factor mRNA by HuR. J Biol Chem 277 13635-629 
13640. 630 
Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD & Matusik RJ 2014 Mouse 631 
models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev 33 632 
377-397. 633 
Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK & Smith GJ 2004 Short-634 
Term Human Prostate Primary Xenografts An in Vivo Model of Human Prostate Cancer 635 
Vasculature and Angiogenesis. Cancer research 64 1712-1721. 636 
Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS & Gallick GE 2005 HIF-637 
1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that 638 
regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate 639 
carcinomas. Oncogene 24 3110-3120. 640 
Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA & Stratford IJ 2007 641 
Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is 642 
prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67 84-90. 643 
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, 644 
Mineur L, Barone C, et al. 2013 Regorafenib monotherapy for previously treated metastatic 645 
colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, 646 
phase 3 trial. Lancet 381 303-312. 647 
Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom 648 
KJ, Salmon A, D'Silva O, Betteridge KB, et al. 2015 Alternative splicing of TIA-1 in human colon 649 
cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab 650 
resistance. Mol Oncol 9 167-178. 651 
Harper SJ & Bates DO 2008 VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev 652 
Cancer 8 880-887. 653 
Page 19 of 33
Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, Hobisch A, Culig Z & 654 
Tindall DJ 2007 Androgen deprivation increases p300 expression in prostate cancer cells. 655 
Cancer Res 67 3422-3430. 656 
Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M & 657 
Mottet N 2013 Early detection of prostate cancer: European Association of Urology 658 
recommendation. Eur Urol 64 347-354. 659 
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev 660 
V, Wiegel T, Zattoni F, et al. 2014 EAU guidelines on prostate cancer. part 1: screening, 661 
diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 124-137. 662 
Hrouda D, Nicol DL & Gardiner RA 2003 The role of angiogenesis in prostate development and 663 
the pathogenesis of prostate cancer. Urol Res 30 347-355. 664 
Huez I, Creancier L, Audigier S, Gensac MC, Prats AC & Prats H 1998 Two independent 665 
internal ribosome entry sites are involved in translation initiation of vascular endothelial growth 666 
factor mRNA. Mol Cell Biol 18 6178-6190. 667 
Huggins C & Hodges C 1941 Studies on Prostatic Cancer. I. The Effect of Castration, of 668 
Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the 669 
Prostate. Cancer Res 1 293-297. 670 
Humphrey PA 2012 Histological variants of prostatic carcinoma and their significance. 671 
Histopathology 60 59-74. 672 
Huntzinger E & Izaurralde E 2011 Gene silencing by microRNAs: contributions of translational 673 
repression and mRNA decay. Nat Rev Genet 12 99-110. 674 
Ikeda E, Achen MG, Breier G & Risau W 1995 Hypoxia-induced transcriptional activation and 675 
increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 676 
270 19761-19766. 677 
Jang SK, Krausslich HG, Nicklin MJ, Duke GM, Palmenberg AC & Wimmer E 1988 A segment 678 
of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of 679 
ribosomes during in vitro translation. J Virol 62 2636-2643. 680 
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, 681 
Ellinger J, Metzger E, et al. 2006 Androgen receptor coactivators lysine-specific histone 682 
demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer 683 
recurrence. Cancer Res 66 11341-11347. 684 
Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster 685 
BA & Greenberg NM 2003 Pathobiology of autochthonous prostate cancer in a pre-clinical 686 
transgenic mouse model. Prostate 55 219-237. 687 
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, 688 
Shido K, Kerns SA, et al. 2005 VEGFR1-positive haematopoietic bone marrow progenitors 689 
initiate the pre-metastatic niche. Nature 438 820-827. 690 
Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, Gudas LJ & Mongan 691 
NP 2013 The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in 692 
prostate cancer. Mol Oncol 7 555-566. 693 
Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja DR, 694 
Rosenberg AZ, Jin S, et al. 2014 CD47 signaling regulates the immunosuppressive activity of 695 
VEGF in T cells. J Immunol 193 3914-3924. 696 
King PH 2000 RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-untranslated 697 
regions using a novel ELISA-based assay. Nucleic Acids Res 28 E20. 698 
Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z & Keller ET 2005 Vascular endothelial 699 
growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 65 700 
10921-10929. 701 
Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ & Vasioukhin V 2004 Hepsin 702 
promotes prostate cancer progression and metastasis. Cancer Cell 6 185-195. 703 
Page 20 of 33
Kooistra SM & Helin K 2012 Molecular mechanisms and potential functions of histone 704 
demethylases. Nat Rev Mol Cell Biol 13 297-311. 705 
Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, 706 
Becker JC & Odum N 2006 Jak3- and JNK-dependent vascular endothelial growth factor 707 
expression in cutaneous T-cell lymphoma. Leukemia 20 1759-1766. 708 
Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, 709 
Thijs V, Andersson J, van Marion I, et al. 2003 VEGF is a modifier of amyotrophic lateral 710 
sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 711 
383-394. 712 
Levy AP, Levy NS & Goldberg MA 1996 Post-transcriptional regulation of vascular endothelial 713 
growth factor by hypoxia. J Biol Chem 271 2746-2753. 714 
Lorente D & De Bono JS 2014 Molecular alterations and emerging targets in castration resistant 715 
prostate cancer. Eur J Cancer 50 753-764. 716 
Maes C, Kobayashi T, Selig MK, Torrekens S, Roth SI, Mackem S, Carmeliet G & Kronenberg 717 
HM 2010 Osteoblast precursors, but not mature osteoblasts, move into developing and 718 
fractured bones along with invading blood vessels. Dev Cell 19 329-344. 719 
Mangoni M, Vozenin MC, Biti G & Deutsch E 2012 Normal tissues toxicities triggered by 720 
combined anti-angiogenic and radiation therapies: hurdles might be ahead. Br J Cancer 107 721 
308-314. 722 
Martin BJ 2013 Inhibiting vasculogenesis after radiation: a new paradigm to improve local 723 
control by radiotherapy. Semin Radiat Oncol 23 281-287. 724 
Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, 725 
Shappell SB & Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops 726 
prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 727 
61 2239-2249. 728 
Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt 729 
DA, Ladomery MR, Harper SJ, Bates DO, et al. 2014 Serine-arginine protein kinase 1 (SRPK1) 730 
inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 731 
Mellman I, Coukos G & Dranoff G 2011 Cancer immunotherapy comes of age. Nature 480 480-732 
489. 733 
Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R & 734 
Schule R 2005 LSD1 demethylates repressive histone marks to promote androgen-receptor-735 
dependent transcription. Nature 437 436-439. 736 
Midy V & Plouet J 1994 Vasculotropin/vascular endothelial growth factor induces differentiation 737 
in cultured osteoblasts. Biochem Biophys Res Commun 199 380-386. 738 
Miller DL, Dibbens JA, Damert A, Risau W, Vadas MA & Goodall GJ 1998 The vascular 739 
endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Lett 434 417-740 
420. 741 
Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, Fong PC, Olmos D, 742 
O'Sullivan JM, Pedley I, et al. 2014 Randomized Phase II trial of nintedanib, afatinib and 743 
sequential combination in castration-resistant prostate cancer. Future Oncol 10 219-231. 744 
Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR & Smith GJ 2012 Primary xenografts of 745 
human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 746 
7 e29623. 747 
Montico F, Kido LA, Hetzl AC & Cagnon VH 2014 Prostatic angiogenic responses in late life: 748 
Antiangiogenic therapy influences and relation with the glandular microenvironment in the 749 
transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate. 750 
Morris MJ, Negishi Y, Pazsint C, Schonhoft JD & Basu S 2010 An RNA G-quadruplex is 751 
essential for cap-independent translation initiation in human VEGF IRES. J Am Chem Soc 132 752 
17831-17839. 753 
Page 21 of 33
Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara 754 
M, Harper SJ, Woolard J, Ladomery MR, et al. 2010 Regulation of vascular endothelial growth 755 
factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic 756 
strategy for angiogenesis. J Biol Chem 285 5532-5540. 757 
Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, 758 
Harper SJ & Bates DO 2008 Expression of pro- and anti-angiogenic isoforms of VEGF is 759 
differentially regulated by splicing and growth factors. J Cell Sci 121 3487-3495. 760 
Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K & 761 
Vaishampayan U 2012 Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic 762 
Castrate-Resistant Prostate Cancer. ISRN Oncol 2012 242850. 763 
Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, 764 
Harper SJ, Ladomery MR & Bates DO 2012 SRPK1 inhibition in vivo: modulation of VEGF 765 
splicing and potential treatment for multiple diseases. Biochem Soc Trans 40 831-835. 766 
Onesto C, Berra E, Grepin R & Pages G 2004 Poly(A)-binding protein-interacting protein 2, a 767 
strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 279 34217-34226. 768 
Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, Yi Z, Qu W & Liu M 2011a (−)-Gossypol 769 
Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling–770 
Mediated Angiogenesis. Molecular cancer therapeutics 10 795-805. 771 
Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB & Liu M 2011b 1′-772 
Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by 773 
targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway. Carcinogenesis 32 904-774 
912. 775 
Pei Z, Lin D, Song X, Li H & Yao H 2008 TLR4 signaling promotes the expression of VEGF and 776 
TGFbeta1 in human prostate epithelial PC3 cells induced by lipopolysaccharide. Cell Immunol 777 
254 20-27. 778 
Pelletier J & Sonenberg N 1988 Internal initiation of translation of eukaryotic mRNA directed by 779 
a sequence derived from poliovirus RNA. Nature 334 320-325. 780 
Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, 781 
Abbondanza C & Avvedimento EV 2008 DNA oxidation as triggered by H3K9me2 demethylation 782 
drives estrogen-induced gene expression. Science 319 202-206. 783 
Porta C, Giglione P, Liguigli W & Paglino C 2015 Dovitinib (CHIR258, TKI258): structure, 784 
development and preclinical and clinical activity. Future Oncol 11 39-50. 785 
Presnell SC, Werdin ES, Maygarden S, Mohler JL & Smith GJ 2001 Establishment of short-term 786 
primary human prostate xenografts for the study of prostate biology and cancer. The American 787 
journal of pathology 159 855-860. 788 
Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T & 789 
Freedland SJ 2013 Management of biochemical recurrence after primary treatment of prostate 790 
cancer: a systematic review of the literature. Eur Urol 64 905-915. 791 
Qi WX, Tang LN, He AN, Shen Z & Yao Y 2011 The role of vandetanib in the second-line 792 
treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized 793 
controlled trials. Lung 189 437-443. 794 
Rahman MM, Miyamoto H, Lardy H & Chang C 2003 Inactivation of androgen receptor 795 
coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in 796 
prostate cancer cells. Proc Natl Acad Sci U S A 100 5124-5129. 797 
Roskoski R, Jr. 2007 Vascular endothelial growth factor (VEGF) signaling in tumor progression. 798 
Crit Rev Oncol Hematol 62 179-213. 799 
Rotili D, Tomassi S, Conte M, Benedetti R, Tortorici M, Ciossani G, Valente S, Marrocco B, 800 
Labella D, Novellino E, et al. 2014 Pan-histone demethylase inhibitors simultaneously targeting 801 
Jumonji C and lysine-specific demethylases display high anticancer activities. J Med Chem 57 802 
42-55. 803 
Page 22 of 33
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, 804 
Shore ND, et al. 2012 Increased survival with enzalutamide in prostate cancer after 805 
chemotherapy. N Engl J Med 367 1187-1197. 806 
Semenas J, Allegrucci C, Boorjian SA, Mongan NP & Persson JL 2012 Overcoming drug 807 
resistance and treating advanced prostate cancer. Curr Drug Targets 13 1308-1323. 808 
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, 809 
Andren O, Johnson LA, et al. 2008 Estrogen-Dependent Signaling in a Molecularly Distinct 810 
Subclass of Aggressive Prostate Cancer. J Natl Cancer Inst 100 815-825. 811 
Sfar S, Hassen E, Saad H, Mosbah F & Chouchane L 2006 Association of VEGF genetic 812 
polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35 21-28. 813 
Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, 814 
Harwood J, Bismar TA, et al. 2004 Androgen-independent prostate cancer is a heterogeneous 815 
group of diseases: lessons from a rapid autopsy program. Cancer Res 64 9209-9216. 816 
Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, 817 
Stark R, Warren AY, Mills IG, et al. 2013 The androgen receptor induces a distinct 818 
transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 23 35-47. 819 
Shih SC & Claffey KP 1999 Regulation of human vascular endothelial growth factor mRNA 820 
stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 274 1359-1365. 821 
Shima DT, Deutsch U & D'Amore PA 1995 Hypoxic induction of vascular endothelial growth 822 
factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 823 
370 203-208. 824 
Siegel RL, Miller KD & Jemal A 2015 Cancer statistics, 2015. CA Cancer J Clin 65 5-29. 825 
Small AC & Oh WK 2012 Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther 12 826 
1241-1249. 827 
Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, 828 
Harzstark AL, Sartor AO, et al. 2014 Cabozantinib in chemotherapy-pretreated metastatic 829 
castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J 830 
Clin Oncol 32 3391-3399. 831 
Sohn EJ, Won G, Lee J, Lee S & Kim SH 2015 Upregulation of miRNA3195 and miRNA374b 832 
Mediates the Anti-Angiogenic Properties of Melatonin in Hypoxic PC-3 Prostate Cancer Cells. J 833 
Cancer 6 19-28. 834 
Sridhar SS, Joshua AM, Gregg R, Booth CM, Murray N, Golubovic J, Wang L, Harris P & Chi 835 
KN 2014 A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients 836 
With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 837 
Sterling JA, Edwards JR, Martin TJ & Mundy GR 2011 Advances in the biology of bone 838 
metastasis: how the skeleton affects tumor behavior. Bone 48 6-15. 839 
Stewart SB & Boorjian SA 2014 Radical prostatectomy in high-risk and locally advanced 840 
prostate cancer: Mayo Clinic perspective. Urol Oncol. 841 
Street J, Bao M, deGuzman L, Bunting S, Peale FV, Jr., Ferrara N, Steinmetz H, Hoeffel J, 842 
Cleland JL, Daugherty A, et al. 2002 Vascular endothelial growth factor stimulates bone repair 843 
by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 99 9656-9661. 844 
Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, 845 
Pettaway CA, et al. 2002 Anti-vascular endothelial growth factor receptor 2 antibody reduces 846 
tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of 847 
endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 848 
production. Clin Cancer Res 8 2714-2724. 849 
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stohr 850 
R, Hartmann A, et al. 2010 The microRNA profile of prostate carcinoma obtained by deep 851 
sequencing. Mol Cancer Res 8 529-538. 852 
Page 23 of 33
Szczyrba J, Nolte E, Hart M, Doll C, Wach S, Taubert H, Keck B, Kremmer E, Stohr R, 853 
Hartmann A, et al. 2013 Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for 854 
microRNAs that are downregulated in prostate carcinoma. Int J Cancer 132 775-784. 855 
Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, Orlandi F, Gravis G, 856 
Matveev V, Bavbek S, et al. 2013 Aflibercept versus placebo in combination with docetaxel and 857 
prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): 858 
a phase 3, double-blind randomised trial. Lancet Oncol 14 760-768. 859 
Tay Y, Zhang J, Thomson AM, Lim B & Rigoutsos I 2008 MicroRNAs to Nanog, Oct4 and Sox2 860 
coding regions modulate embryonic stem cell differentiation. Nature 455 1124-1128. 861 
Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von 862 
Eschenbach AC & Chung LW 1994 Androgen-independent cancer progression and bone 863 
metastasis in the LNCaP model of human prostate cancer. Cancer Res 54 2577-2581. 864 
Tombal B, Alcaraz A, James N, Valdagni R & Irani J 2014 Can we improve the definition of 865 
high-risk, hormone naive, non-metastatic prostate cancer? BJU Int 113 189-199. 866 
Van Der Kelen K, Beyaert R, Inze D & De Veylder L 2009 Translational control of eukaryotic 867 
gene expression. Crit Rev Biochem Mol Biol 44 143-168. 868 
Vuky J, Pham HT, Warren S, Douglass E, Badiozamani K, Madsen B, Hsi A & Song G 2012 869 
Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated 870 
radiation therapy (IMRT) in high-risk prostate cancer. Int J Radiat Oncol Biol Phys 82 e609-615. 871 
Walczak R, Joseph SB, Laffitte BA, Castrillo A, Pei L & Tontonoz P 2004 Transcription of the 872 
vascular endothelial growth factor gene in macrophages is regulated by liver X receptors. J Biol 873 
Chem 279 9905-9911. 874 
Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, 875 
Aparicio A, Ravoori MK, et al. 2014 Prostate cancer cell-stromal cell crosstalk via FGFR1 876 
mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med 6 252ra122. 877 
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al. 878 
2009 Androgen receptor regulates a distinct transcription program in androgen-independent 879 
prostate cancer. Cell 138 245-256. 880 
Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, 881 
Nelson PS, et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene 882 
leads to metastatic prostate cancer. Cancer Cell 4 209-221. 883 
Wegiel B, Bjartell A, Ekberg J, Gadaleanu V, Brunhoff C & Persson JL 2005 A role for cyclin A1 884 
in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. 885 
Oncogene 24 6385-6393. 886 
Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, Nilsson E, Otterbein L, 887 
Härkönen P & Persson JL 2008 Multiple cellular mechanisms related to cyclin A1 in prostate 888 
cancer invasion and metastasis. J Natl Cancer Inst 100 1022-1036. 889 
Weiner AB, Patel SG & Eggener SE 2015 Pathologic outcomes for low-risk prostate cancer 890 
after delayed radical prostatectomy in the United States. Urol Oncol. 891 
Wong SY, Haack H, Crowley D, Barry M, Bronson RT & Hynes RO 2005 Tumor-secreted 892 
vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but 893 
lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 65 9789-9798. 894 
Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, 895 
Waine E, Perrin R, et al. 2004 VEGF165b, an inhibitory vascular endothelial growth factor splice 896 
variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein 897 
expression. Cancer Res 64 7822-7835. 898 
Wu J, Richer J, Horwitz KB & Hyder SM 2004 Progestin-dependent induction of vascular 899 
endothelial growth factor in human breast cancer cells: preferential regulation by progesterone 900 
receptor B. Cancer Res 64 2238-2244. 901 
Wu X, Gong S, Roy-Burman P, Lee P & Culig Z 2013 Current mouse and cell models in 902 
prostate cancer research. Endocr Relat Cancer 20 R155-170. 903 
Page 24 of 33
Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y & Ochiai 904 
A 2001 Establishment of a novel species-and tissue-specific metastasis model of human 905 
prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice 906 
engrafted with human adult lung and bone. Cancer research 61 2177-2182. 907 
Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, et al. 2010 An 908 
integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in 909 
prostate cancer progression. Cancer Cell 17 443-454. 910 
Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q & Tao R 2012 MicroRNA-205 functions as a tumor 911 
suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep 27 1200-1206. 912 
Yun H, Lee M, Kim SS & Ha J 2005 Glucose deprivation increases mRNA stability of vascular 913 
endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate 914 
carcinoma. J Biol Chem 280 9963-9972. 915 
Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 916 
2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate 917 
cancer. Cancer Res 66 7889-7898. 918 
Zhuang HQ, Yuan ZY & Wang P 2014 Research progress on the mechanisms of combined 919 
bevacizumab and radiotherapy. Recent Pat Anticancer Drug Discov 9 129-134. 920 
 921 
 922 
Page 25 of 33
Figure Legends 
 
 
Figure 1. A. Immunohistochemical analysis of the expression of cyclin A1 (a,b,c), vascular 
endothelial growth factor (VEGF) (d,e,f) and prostate specific antigen (PSA) (c,f,i) in benign 
prostate hyperplasia (a,d,g) and moderately (b,e,h) and poorly differentiated (c,f,i) PCa 
specimens. Adapted and reproduced with permission from (Wegiel et al. 2005). B. 
Evaluation of vascular endothelial growth factor (VEGF) in PCa specimens. Tissue 
microarrays of sections from benign tissue and adjacent tumor tissue designated as Gleason 
grade 3 (81%) or Gleason grade 4–5 (18%) were immunostained with antibodies against 
VEGF. Differences in the expression of VEGF (tumor n = 864, benign n = 787), between 
groups were assessed using the paired Wilcoxon signed rank test (P < .001). The mean 
values of intensities of staining (horizontal lines) with error bars representing 95% 
confidence intervals for the mean are shown. The outliers are labelled by open circles. The 
boxes represent the distribution of the expression of each protein in the groups. The dot plot 
shows the expression of genes encoding VEGF in tumour specimens from patients with BPH 
(n = 6), primary PCa (n = 7), and metastatic PCa (Met, n = 6), analysed by cDNA microarray. 
Differences between metastatic cancers (Met) and nonmetastatic disease (benign PCa and 
primary tumours in localized cancer) were assessed using the Mann-Whitney test. P values 
from two-sided tests are indicated. Adapted and reproduced with permission from (Wegiel, et 
al. 2008). 
 
Figure 2. (A). The VEGF promoter is regulated by a diverse array of transcription factors 
hypoxia-inducible factors (HIFs), specificity protein-1 (Sp1) and most notably in the context 
of this review, multiple nuclear receptors including the androgen (Eisermann et al. 2013), 
estrogen  (Buteau-Lozano et al. 2002; Dadiani et al. 2009) indicated in red and yellow 
respectively. IN addition the VEGF promoter is regulated by progesterone (Wu et al. 2004), 
vitamin D (Cardus et al. 2009) and the liver-X nuclear receptors (LXR) (Walczak et al. 2004). 
Nuclear receptors recruit multiple, enzymatically diverse epigenetic coregulators including 
p160/p300 lysine acetyltransferase, demethylases which cooperate with the mediator 
complex to stabilize recruitment of the basal transcriptional machinery and RNA polymerase 
II. (B) Evidence from genomewide chromatin immuno-precipitation studies indicate 
recruitment of AR in LNCaP, 22Rv1, VCaP PCa cells (GSM698597)(Sharma, et al. 2013) 
and ERα in VCaP (GSM1076110) (Chakravarty, et al. 2014) to the VEGF promoter. (C) 
Positions of microRNA target sites and Internal Ribosome Entry Sites (IRES) in relation to 
the coding sequence of the VEGF.  
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Figure 3. VEGF influences multiple convergent mechanisms contributing to metastases. 
VEGF promotes angiogenesis in response to intra-tumoral hypoxia and deregulated hypoxia 
inducible factor function (A), promotes local invasion and distant metastases by facilitating 
PCa cell colonisation of niches within the bone marrow (B) and suppresses function of 
cytotoxic T, anti-tumor macrophages  and dendritic cells thereby enabling disseminating 
tumor cells to evade immune surveillance (C).   
 
Figure 4.  Therapies targeting receptor tyrosine (RTK) activity of VEGF receptors. Results 
have been disappointing for nintedanib (Molife, et al. 2014). However dovitinib, (Porta, et al. 
2015; Wan, et al. 2014). cabozantinib (Smith, et al. 2014), pazopanib (Sridhar, et al. 2014), 
axitinib (Eswaraka, et al. 2014) have shown some promising activity in patient subsets in 
PCa clinical trials or pre-clinical models. The structures of FDA approved RTK inhibitors, 
sorafenib and sunitinib, are shown for comparison. Trials of tivozanib are underway 
(NCT01885949). 
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Table 1. Selected mouse models for the study of prostate cancer (PCa) progression. 
 
Model PCa type Metastasis CRPC model  NE PCa 
model  
VEGF studies 
Mouse xenografts       
LNCaP (Sublines: LNCaP-
Pro3-5, LNCaP-LN3-4, 
LNCaP-IL6, LNCap-abl, 
LNCaP C4-2) 
AD, MC V, L NR No (Sweeney et al., 
2002) 
PC3 (Subline: PC3M, PC3-AR, 
PC-3M-LN4, PC-3M-luc-C6, 
PC-3M-Pro4) 
AD, MC V, B, L Yes No (Pang et al., 2011a 
and 2011b, Anai et 
al., 2011) 
WISH-PC2 MC, NE V, L Yes Yes NR 
LTL352, LTL370 MC, NE Yes, NR Yes Yes NR 
Genetically engineered mice      
TRAMP AD, NE V, B, L Yes Yes (Montico et al. 2014) 
LADY (12T-7s-f/PB-hepsin) MC, NE V, B NR Yes NR 
LADY (12T-10) MC, NE V, B, L NR  Yes NR 
P53
PE-/-
 Rb
PE-/-
 MC, NE V,L Yes Yes NR 
Pten 
flox/flox
  MC V, L Yes No (Geretti et al. 2010) 
Pten 
flox/flox
 NKX3.1-Cre
ERT2
 AD L Yes NR NR 
Pten 
flox/flox
 NKX3.1-Cre
ERT2
Braf 
LSLflox/+
 
AD, MC V, L NR NR NR 
Pten 
flox/flox
 NKX3.1-
Cre
ERT2
Kras 
LSLflox/+
 
AD, MC V, L NR NR NR 
Pten 
flox/flox
, Smad4 
flox/flox
 MC V, L NR NR NR 
Z-Myc, Pten 
flox/+
, p53 
flox/flox
 AD, MC L, B NR No NR 
 
AD: adenocarcinoma; MC: metastatic carcinoma; AI: androgen independent; NE: neuroendocrine, 
CRPC: castrate-resistant prostate cancer (PCa); SQ: squamous differentiation; V: visceral; B: bone; 
L: lymp nodes; NR not reported 
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Figure 1. A. Immunohistochemical analysis of the expression of cyclin A1 (a,b,c), vascular endothelial 
growth factor (VEGF) (d,e,f) and prostate specific antigen (PSA) (c,f,i) in benign prostate hyperplasia (a,d,g) 
and moderately (b,e,h) and poorly differentiated (c,f,i) PCa specimens. Adapted and reproduced with 
permission from (Wegiel et al. 2005). B. Evaluation of vascular endothelial growth factor (VEGF) in PCa 
specimens. Tissue microarrays of sections from benign tissue and adjacent tumor tissue designated as 
Gleason grade 3 (81%) or Gleason grade 4–5 (18%) were immunostained with antibodies against VEGF. 
Differences in the expression of VEGF (tumor n = 864, benign n = 787), between groups were assessed 
using the paired Wilcoxon signed rank test (P < .001). The mean values of intensities of staining (horizontal 
lines) with error bars representing 95% confidence intervals for the mean are shown. The outliers are 
labelled by open circles. The boxes represent the distribution of the expression of each protein in the 
groups. The dot plot shows the expression of genes encoding VEGF in tumour specimens from patients with 
BPH (n = 6), primary PCa (n = 7), and metastatic PCa (Met, n = 6), analysed by cDNA microarray. 
Differences between metastatic cancers (Met) and nonmetastatic disease (benign PCa and primary tumours 
in localized cancer) were assessed using the Mann-Whitney test. P values from two-sided tests are indicated. 
Adapted and reproduced with permission from (Wegiel, et al. 2008).  
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Figure 2. (A). The VEGF promoter is regulated by a diverse array of transcription factors hypoxia-inducible 
factors (HIFs), specificity protein-1 (Sp1) and most notably in the context of this review, multiple nuclear 
receptors including the androgen (Eisermann et al. 2013), estrogen  (Buteau-Lozano et al. 2002; Dadiani et 
al. 2009) indicated in red and yellow respectively. IN addition the VEGF promoter is regulated by 
progesterone (Wu et al. 2004), vitamin D (Cardus et al. 2009) and the liver-X nuclear receptors (LXR) 
(Walczak et al. 2004). Nuclear receptors recruit multiple, enzymatically diverse epigenetic coregulators 
including p160/p300 lysine acetyltransferase, demethylases which cooperate with the mediator complex to 
stabilize recruitment of the basal transcriptional machinery and RNA polymerase II. (B) Evidence from 
genomewide chromatin immuno-precipitation studies indicate recruitment of AR in LNCaP, 22Rv1, VCaP PCa 
cells (GSM698597)(Sharma, et al. 2013) and ERα in VCaP (GSM1076110) (Chakravarty, et al. 2014) to the 
VEGF promoter. (C) Positions of microRNA target sites and Internal Ribosome Entry Sites (IRES) in relation 
to the coding sequence of the VEGF.    
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Figure 3. VEGF influences multiple convergent mechanisms contributing to metastases. VEGF promotes 
angiogenesis in response to intra-tumoral hypoxia and deregulated hypoxia inducible factor function (A), 
promotes local invasion and distant metastases by facilitating PCa cell colonisation of niches within the bone 
marrow (B) and suppresses function of cytotoxic T, anti-tumor macrophages  and dendritic cells thereby 
enabling disseminating tumor cells to evade immune surveillance (C).    
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Figure 4.  Therapies targeting receptor tyrosine (RTK) activity of VEGF receptors. Results have been 
disappointing for nintedanib (Molife, et al. 2014). However dovitinib, (Porta, et al. 2015; Wan, et al. 2014). 
cabozantinib (Smith, et al. 2014), pazopanib (Sridhar, et al. 2014), axitinib (Eswaraka, et al. 2014) have 
shown some promising activity in patient subsets in PCa clinical trials or pre-clinical models. The structures 
of FDA approved RTK inhibitors, sorafenib and sunitinib, are shown for comparison. Trials of tivozanib are 
underway (NCT01885949).  
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